<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Varicella virus vaccine (VAR): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Varicella virus vaccine (VAR): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Varicella virus vaccine (VAR): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10038" href="/d/html/10038.html" rel="external">see "Varicella virus vaccine (VAR): Drug information"</a> and <a class="drug drug_patient" data-topicid="11925" href="/d/html/11925.html" rel="external">see "Varicella virus vaccine (VAR): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233527"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Varivax</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868577"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Varilrix;</li>
<li>Varivax III</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1062852"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Vaccine</span>;</li>
<li>
<span class="list-set-name">Vaccine, Live Virus</span></li></ul></div>
<div class="block dop drugH1Div" id="F233537"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered ≤4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="937db9e2-a48f-4ad7-9c9f-6b65d8ae8b3e">Primary immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Primary immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">CDC/ACIP recommendations: Children ≥12 months: IM, SUBQ: ~0.5 mL (entire contents of reconstituted vial) per dose for a total of 2 doses administered as follows: 12 to 15 months of age and 4 to 6 years of age. The second dose may be administered earlier provided ≥3 months have elapsed after the first dose. If the second dose was administered ≥4 weeks after the first dose, it may be considered as valid (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i> National Advisory Committee on Immunization (NACI) recommends 2 doses of 0.5 mL with first dose administered at 12 to 15 months of age. Separate doses by ≥3 months; however, if rapid protection is necessary, may administer second dose after ≥4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children:</p>
<p style="text-indent:-2em;margin-left:8em;">Varilrix: SUBQ: 2 doses of 0.5 mL separated by ≥6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Varivax III: SUBQ: ~0.5 mL (entire contents of reconstituted vial) as a single dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Adolescents: <b>Note:</b> The NACI recommends that adolescents should receive 2 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Varilrix: SUBQ: 2 doses of 0.5 mL separated by ≥6 weeks.</p>
<p style="text-indent:-2em;margin-left:8em;">Varivax III: SUBQ: 2 doses of ~0.5 mL (entire contents of reconstituted vial) separated by 4 to 8 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="030231b8-f8a7-4a85-8830-e75f8b3f4505">Catch-up immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Catch-up immunization:</b> Children and Adolescents: ACIP recommendations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>): <b>Note:</b> Do not restart the series. If doses have been given, begin the below schedule at the applicable dose number. IM, SUBQ: ~0.5 mL (entire contents of reconstituted vial) per dose for a total of 2 doses administered as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">First dose given on the elected date.</p>
<p style="text-indent:-2em;margin-left:4em;">Second dose given at least 3 months after the first dose (if age &lt;13 years) or at least 4 weeks after the first dose (if age ≥13 years).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd3887c3-2672-4227-a8c1-7d4760e48451">Varicella postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella postexposure prophylaxis (healthy, previously unvaccinated individuals):</b> Children (≥12 months) and Adolescents: IM, SUBQ: ~0.5 mL (entire contents of reconstituted vial) administered ideally within 72 hours postexposure but may be used up to 120 hours (5 days) postexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51193243"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51193244"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F233531"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10038" href="/d/html/10038.html" rel="external">see "Varicella virus vaccine (VAR): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="74c43efa-3169-4d3d-9b17-8c8eeaa06bfb">Varicella immunization</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella immunization:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>US labeling:</i>
<b>IM or SUBQ: </b>Two doses of ~0.5 mL (entire contents of reconstituted vial) separated by ≥4 weeks (4 to 8 weeks apart per ACIP). <b>Note:</b> The ACIP recommends that all children and adults without evidence of immunity receive 2 doses of the vaccine; those who received only 1 dose of a varicella-containing vaccine receive a second dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Canadian labeling:</i>
<b>Note:</b> The NACI recommends that adolescents (≥13 years of age) and adults (&lt;50 years of age) who received only 1 dose of vaccine receive a second dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NACI.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NACI.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Varilrix: <b>SUBQ: </b>Two single doses 0.5 mL separated by ≥6 weeks.</p>
<p style="text-indent:-2em;margin-left:6em;">Varivax III: <b>SUBQ: </b>Two single doses ~0.5 mL (entire contents of reconstituted vial) separated by 4 to 8 weeks.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fd3887c3-2672-4227-a8c1-7d4760e48451">Varicella postexposure prophylaxis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Varicella postexposure prophylaxis (healthy, previously unvaccinated individuals) (off-label use):</b>
<b>IM, SUBQ:</b> ~0.5 mL (entire contents of reconstituted vial) administered ideally within 72 hours postexposure but may be used up to 120 hours (5 days) postexposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17585291']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17585291'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990893"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling</p></div>
<div class="block doha drugH1Div" id="F50988163"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling</p></div>
<div class="block adr drugH1Div" id="F233504"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for children, adolescents, and adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction (19% to 33%; including erythema at injection site, hematoma at injection site, induration at injection site, injection-site numbness, injection-site pruritus, pain at injection site, rash at injection site, swelling at injection site, and stiffness)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (10% to 15%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus, skin rash, varicella-like rash (≤6%; at injection site and generalized)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills, fatigue, headache, irritability, malaise, sleep disturbance</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, myalgia, neck stiffness</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Otitis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, lower respiratory signs and symptoms, upper respiratory system symptoms</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Herpes zoster infection</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Febrile seizures (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema, syncope</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, secondary skin infection (including cellulitis and impetigo), Stevens-Johnson syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, Henoch-Schönlein purpura, immune thrombocytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock, anaphylaxis, angioedema, facial edema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis, ataxia, Bell palsy, cerebrovascular accident, dizziness, encephalitis, Guillain-Barré syndrome, meningitis, paresthesia, seizure, transverse myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior uveitis (children; Krall 2014), keratitis (children; Krall 2014), necrotizing retinitis (immunocompromised patients)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pharyngitis, pneumonia</p></div>
<div class="block coi drugH1Div" id="F233517"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Severe allergic or anaphylactic reaction to the vaccine, a previous dose of a varicella-containing vaccine, or any component of the formulation, including neomycin and gelatin; immunosuppressed or immunodeficient individuals due to disease or medical therapy; untreated tuberculosis (TB) disease (active TB); active febrile illness with fever &gt;38.5°C (&gt;101.3°F); pregnancy or planning to become pregnant within the next 3 months.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Varivax III: Blood dyscrasias, leukemia, lymphomas (any type), or other malignancies affecting the bone marrow or lymphatic system; concomitant use with immunosuppressive therapy (including high-dose corticosteroids); primary or acquired immunodeficiency, including immunosuppression associated with AIDS or other clinical manifestations of infection with HIV (excludes immunosuppression in asymptomatic children with CD4 T-lymphocyte percentages ≥25%); family history of congenital or hereditary immunodeficiency (unless immune competence of vaccine recipient is demonstrated). Varilrix: Primary or acquired immunodeficiency with a total lymphocyte count &lt;1,200/mm<sup>3</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F233502"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• CNS infection: Cases of encephalitis or meningitis caused by vaccine strain varicella virus have been reported in immunocompetent individuals previously vaccinated with varicella virus vaccine months to years after vaccination. Cases are often associated with preceding or concurrent herpes zoster rash.</p>
<p style="text-indent:-2em;margin-left:4em;">• Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute illness: Although fever is a contraindication per the manufacturer, current guidelines allow for administration to patients with mild acute illness with or without low grade fever (CDC/ACIP [Marin 2007]). Defer administration in patients with moderate or severe acute illness (with or without fever) (ACIP [Kroger 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Altered immunocompetence: Use of this vaccine is contraindicated in persons who are immunosuppressed or immunodeficient. Household and close contacts of persons with altered immunocompetence may receive most age-appropriate vaccines (ACIP [Kroger 2023]). Live vaccines should be administered ≥4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2023]; IDSA [Rubin 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV: Children ≤8 years of age with HIV infection with age-specific CD4+ T-lymphocyte percentages ≥15% may receive live attenuated varicella vaccine. Vaccination may also be considered for children &gt;8 years of age, adolescents, and adults with CD4+ T-lymphocyte counts ≥200 cells/microliter; refer to guidelines for specific information (CDC/ACIP [Marin 2007]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody-containing products: Varicella vaccine and antibody-containing products (eg, immune globulin, blood products) should <b>not</b> be administered simultaneously. Guidelines with suggested administration intervals are available (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Antiviral drugs: Medications active against the herpesvirus family (eg, acyclovir, famciclovir, valacyclovir) may interfere with the varicella vaccine; avoid varicella vaccination to a patient who has received these antivirals 24 hours before vaccination; avoid use of these antiviral agents for 14 days after varicella vaccination (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Salicylates: Avoid salicylates in children and adolescents 12 months through 17 years of age for 6 weeks after vaccination; varicella may increase the risk of Reye syndrome.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or non-live) for which a person is eligible at a single visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Albumin: Products may contain albumin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gelatin: Products may contain gelatin. Use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin.</p>
<p style="text-indent:-2em;margin-left:4em;">• Neomycin: Products may contain neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin. Contact dermatitis due to neomycin is not a contraindication to the vaccine (CDC/ACIP [Marin 2007]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use:</p>
<p style="text-indent:-2em;margin-left:6em;">- Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the annual ACIP Recommended Immunization Schedules (refer to the Centers for Disease Control and Prevention [CDC] schedule for detailed information). Specific recommendations for use of this vaccine in immunocompromised patients with asplenia, cancer, HIV infection, cerebrospinal fluid leaks, cochlear implants, hematopoietic stem cell transplant (prior to or after), sickle cell disease, solid organ transplant (prior to or after), or those receiving immunosuppressive therapy for chronic conditions as well as contacts of immunocompromised patients are available from the IDSA (Rubin 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">- Varilrix and Varivax III [Canadian products]: Canadian National Advisory Committee on Immunization (NACI) suggests that Varivax III and Varilrix may also be used for select groups (NACI 2017). Consult product labeling and/or NACI for specific recommendations regarding appropriate use in high risk patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2023]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">• Congenital or hereditary immunodeficiency: Defer use in patients with a family history of congenital or hereditary immunodeficiency until immune competence in the vaccine recipient is demonstrated (CDC/ACIP [Marin 2007]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2023]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Transmission of virus: Transmission of varicella vaccine virus resulting in varicella infection may occur (rare) between vaccine recipients (with or without varicella-like rash) and contacts susceptible to varicella (including healthy and high-risk individuals). The manufacturer notes that vaccinated individuals should not have close association with susceptible high-risk individuals for up to 6 weeks following vaccination. High-risk individuals include immunocompromised persons, pregnant women without evidence of immunity, newborns of mothers without evidence of immunity, and all infants born &lt;28 weeks' gestation (regardless of maternal immunity). However, the CDC recommends that vaccine recipients who develop a vaccine-related rash avoid contact with susceptible individuals at high risk for complications until the lesions are resolved (crusted over or fade away) or until no new lesions appear for 24 hours. According to the CDC guidelines, having a pregnant household member is not a contraindication to vaccination (CDC/ACIP [Marin 2007]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F54340189"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Herpes zoster caused by vaccine-strain varicella zoster virus (VZV) has been reported rarely in children postvaccination with varicella virus vaccine; in patients with herpes zoster caused by vaccine-strain VZV, the rash was more likely to correspond to site of vaccine injection than in patients with herpes zoster caused by wild-type VZV (Guffey 2017; Weinmann 2013). Onset of rash at previous injection site occurred between 6 and 61 months postvaccination in a case series describing 7 patients (age range: 1 to 6 years) with herpes zoster; precipitating factors and symptoms varied (Song 2018).</p></div>
<div class="block foc drugH1Div" id="F233511"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Subcutaneous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Varivax: 1350 PFU/0.5 mL (1 ea) [contains albumin bovine, edetic acid (edta), neomycin]</p></div>
<div class="block geq drugH1Div" id="F233498"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16324073"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Injection</b> (Varivax Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1350 pfu/0.5 mL (per each): $209.04</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868578"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Injectable, Subcutaneous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Varilrix: 2000 PFU/0.5 mL (0.5 mL) [contains lactose, neomycin sulfate]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Varivax III: 1350 PFU/0.5 mL (0.5 mL) [contains albumin bovine, neomycin]</p></div>
<div class="block adip drugH1Div" id="F53568990"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Evidence of immunity to varicella includes any of the following (CDC/ACIP [Marin 2007]):</p>
<p style="text-indent:-2em;margin-left:4em;">Documentation of age-appropriate vaccination with varicella vaccine.</p>
<p style="text-indent:-2em;margin-left:4em;">Laboratory evidence of immunity or laboratory confirmation of disease.</p>
<p style="text-indent:-2em;margin-left:4em;">Birth in the United States prior to 1980 (except for health care personnel, pregnant women, and the immunocompromised).</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnosis or verification of varicella disease by health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">Diagnosis or verification of herpes zoster by health care provider.</p></div>
<div class="block admp drugH1Div" id="F52614001"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral:</p>
<p style="text-indent:-2em;margin-left:2em;">IM, SUBQ: Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope-related injuries, adolescents should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>US labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">IM, SUBQ: For IM or SUBQ injection only; do not administer IV. Administer immediately following reconstitution. Administer SUBQ over the anterolateral thigh or into the upper arm (over the triceps area) or administer IM into the anterolateral aspect of the thigh or the outer aspect of the upper arm (deltoid muscle) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i></p>
<p style="text-indent:-2em;margin-left:4em;">SUBQ: For SUBQ injection only; do not administer IM, IV, intravascularly, or intradermally. Varilrix is to be administered SUBQ in the deltoid region only. Varivax III should preferentially be administered SUBQ in the deltoid region or anterolateral thigh. Administer immediately following reconstitution.</p></div>
<div class="block adm drugH1Div" id="F233514"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection. To prevent syncope related injuries, patients should be vaccinated while seated or lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kroger.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kroger.2'])">Ref</a></span>). US law requires that the date of administration, the vaccine manufacturer, lot number of vaccine, Vaccine Information Statement (VIS) edition date and date it was provided, and the administering person's name, title, and address be recorded.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>US labeling:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IM, SUBQ:</b> For IM or SUBQ injection only. Administer immediately following reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Canadian labeling:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>SUBQ:</b> For SUBQ injection only; do not administer IM, IV, intravascularly or intradermally. Varilrix is to be administered SUBQ in the deltoid region only. Varivax III should preferentially be administered SUBQ in the deltoid region or anterolateral thigh. Administer immediately following reconstitution.</p></div>
<div class="block sts drugH1Div" id="F3149412"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Prior to reconstitution and during shipping, store vaccine in freezer at −50°C to −15°C (−58°F to 5°F). Use of dry ice may subject vaccine to temperatures colder than −50°C (−58°F). Vaccine may be stored under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 72 hours. Protect from light. Store diluent at room temperature of 20°C to 25°C (68°F to 77°F) or in refrigerator. Administer immediately following reconstitution; do not freeze; discard reconstituted vaccine if not used within 30 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Varilrix (Canadian product): Prior to reconstitution, store vaccine under refrigeration at 2°C to 8°C (36°F to 46°F). Vaccine not affected by freezing. Store diluent at 25°C (77°F) or under refrigeration. Following reconstitution, vaccine may be stored for 90 minutes at 25°C (77°F) or up to 8 hours under refrigeration. Discard if not used within recommended times.</p>
<p style="text-indent:-2em;margin-left:2em;">Varivax III (Canadian product): During shipping, store vaccine at −50°C to 8°C (−58°F to 46°F); use of dry ice may subject vaccine to temperatures colder than −50°C (−58°F). Prior to reconstitution store vaccine under refrigeration at 2°C to 8°C (36°F to 46°F) for up to 24 months; may also store in freezer at temeratures above −50°C (−58°F); vaccine may be returned to freezer if stored in refrigerator. Prior to reconstitution vaccine may still be use if time out of refrigeration does not exceed 25°C (77°F) for more than 6 hours. Protect from light. Store diluent separately at room temperature of 20°C to 25°C (68°F to 77°F) or in refrigerator; do not freeze. Following reconstitution, vaccine may be stored for 90 minutes at 20°C to 25°C (68°F to 77°F); do not freeze. Discard if not used within recommended time.</p></div>
<div class="block meg drugH1Div" id="F25734153"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient/caregiver before administering each dose of this vaccine; the VIS edition date and date it was provided to the patient/caregiver should be recorded as required by US law; VIS is available at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.cdc.gov%2Fvaccines%2Fhcp%2Fvis%2Fvis-statements%2Fvaricella.html&amp;token=cu87LluU46tfb8AQrnF08l2iRrqpuyci3mb1WXy8U6cPS%2F36hKXF8TxDewl%2FsQb1QTzYOVzkJQYY9H%2BbhxbC5bMvy8ZkGKBoGd7jAgBpekA%3D&amp;TOPIC_ID=13006" target="_blank">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/varicella.html</a>.</p></div>
<div class="block usep drugH1Div" id="F53569429"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Active immunization for the prevention of varicella (FDA approved in ages ≥12 months and adults).</p>
<p style="text-indent:0em;margin-top:2em;">The ACIP (CDC/ACIP [Marin 2007]) recommends vaccination for all children, adolescents, and adults who do not have evidence of immunity. Vaccination is especially important for:</p>
<p style="text-indent:0em;margin-left:2em;">• Health care personnel</p>
<p style="text-indent:0em;margin-left:2em;">• Persons with close contact to those at high risk for severe disease</p>
<p style="text-indent:0em;margin-left:2em;">• Persons living or working in environments where transmission is likely (teachers, childcare workers, residents, and staff of institutional settings)</p>
<p style="text-indent:0em;margin-left:2em;">• Persons in environments where transmission has been reported</p>
<p style="text-indent:0em;margin-left:2em;">• Nonpregnant persons who may become pregnant</p>
<p style="text-indent:0em;margin-left:2em;">• Adolescents and adults in households with children</p>
<p style="text-indent:0em;margin-left:2em;">• International travelers</p>
<p style="text-indent:0em;margin-top:2em;">Postexposure prophylaxis: Vaccination within 3 days (possibly 5 days) after exposure to rash is effective in preventing illness or modifying severity of disease (CDC/ACIP [Marin 2007]).</p>
<p style="text-indent:0em;margin-top:2em;">
<i>Additional Canadian labeling: </i>Varilrix (Canadian product): Also approved for use in high-risk patients (eg, acute leukemia [complete remission and lymphocyte count ≥1,200/mm<sup>3</sup> or that no other evidence of lack of cellular immune competence exists], planned organ transplantation [6 to 8 weeks prior to], receiving immunosuppressive treatment [with lymphocyte count ≥1,200/mm<sup>3</sup>], or other chronic diseases); approved for use in susceptible healthy contacts of high-risk patients.</p></div>
<div class="block mst drugH1Div" id="F233548"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Varicella virus vaccine has been given in error (instead of the indicated varicella immune globulin) to pregnant women exposed to varicella.</p>
<p style="text-indent:-2em;margin-left:4em;">VAR (varicella vaccine) may be confused with HZV (herpes zoster vaccine)</p>
<p style="text-indent:2em;">Varivax may be confused with VZIG</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Other safety concerns:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Both varicella vaccine and zoster vaccine are live, attenuated strains of varicella-zoster virus. Their indications, dosing, and composition are distinct. Varicella is indicated in children to prevent chickenpox, while zoster vaccine is indicated in older individuals to prevent reactivation of the virus which causes shingles. Zoster vaccine is <b>not</b> a substitute for varicella vaccine and should not be used in children.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13300208"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F233505"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections. Management: Avoid administration of salicylates for at least 6 weeks after adminstration of a varicella virus-containing vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of acetaminophen before or during vaccine administration when possible. Acetaminophen is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acyclovir-Valacyclovir: May diminish the therapeutic effect of Varicella Virus Vaccine. Management: When possible, avoid use of acyclovir or valacyclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of these antiviral agents for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anti-CD20 B-Cell Depleting Therapies: May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Anti-CD20 B-Cell Depleting Therapies may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Corticosteroids (Systemic) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Non-US labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment. US labeling states that safety and effectiveness of live vaccines administered with dimethyl fumarate has not been assessed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elivaldogene Autotemcel: May enhance the adverse/toxic effect of Vaccines. Specifically, there may be a greater risk for contracting an infection from any live vaccine. Elivaldogene Autotemcel may diminish the therapeutic effect of Vaccines. Management: Administration of vaccines is not recommended in the 6 weeks before myeloablative conditioning, and until hematologic recovery after elivaldogene autotemcel treatment.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccine-associated infection may be increased. Etrasimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Famciclovir: May diminish the therapeutic effect of Varicella Virus Vaccine. Management: When possible, avoid use of famciclovir within the 24 hours prior to administration of the varicella vaccine, and avoid use of famciclovir for 14 days after vaccination.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Live organism vaccination should be withheld for as long as 6 to 11 months following immune globulin administration. Recommendations vary by product and immune globulin dose, see full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Cytotoxic Chemotherapy) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): Mumps- Rubella- or Varicella-Containing Live Vaccines may enhance the adverse/toxic effect of Immunosuppressants (Miscellaneous Oncologic Agents). Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Miscellaneous Oncologic Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Immunosuppressants (Therapeutic Immunosuppressant Agents) may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May diminish the therapeutic effect of Vaccines (Live).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Methotrexate may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The risk of developing a clinical infection from the live vaccine may be increased. Ozanimod may diminish the therapeutic effect of Varicella Virus-Containing Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propacetamol: May diminish the therapeutic effect of Vaccines. Management: Consider avoiding routine prophylactic use of propacetamol before or during vaccine administration when possible. Propacetamol is still recommended to treat fevers and/or pain that occurs after vaccination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rho(D) Immune Globulin: May diminish the therapeutic effect of Varicella Virus Vaccine. Management: Do not delay administration of the varicella virus vaccine in women who have recently received Rho (D) immune globulin.  If possible, women should be tested 3 or more months after vaccine administration to ensure immunity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Specifically, the risk for Reye's syndrome may increase.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Smallpox Vaccine Live: May enhance the adverse/toxic effect of Varicella Virus Vaccine. It may be difficult to determine which vaccine caused skin lesions or other adverse effects. Management: Separate the administration of smallpox and varicella vaccines by at least 4 weeks.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines. Specifically, the risk of vaccine-associated infection may be increased. Teplizumab may diminish the therapeutic effect of Mumps- Rubella- or Varicella-Containing Live Vaccines.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teplizumab: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of vaccines-associated infection may be increased. Teplizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezepelumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tildrakizumab: May enhance the adverse/toxic effect of Vaccines (Live). The risk for contracting an infection from the vaccine may be increased. Tildrakizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tralokinumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: It is preferable to administer live vaccines simultaneously with tuberculin tests. If a live vaccine has been recently administered, the tuberculin skin test should be administered 4 to 6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53632820"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Varicella virus vaccine is contraindicated for use in patients planning to become pregnant within 3 months (per manufacturer labeling); pregnancy should be avoided for 1 month (per ACIP) following vaccination (CDC/ACIP [Marin 2007]).</p></div>
<div class="block pri drugH1Div" id="F233519"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Varicella virus vaccine is contraindicated for use in pregnant patients.</p>
<p style="text-indent:0em;margin-top:2em;">Information related to pregnancy and fetal outcomes following inadvertent exposure to the varicella virus vaccine was collected from 1995-2013 using the manufacturer's pregnancy registry. Data was available from 905 women who received a varicella containing vaccine (30% within 3 months prior to conception) and who had known pregnancy outcomes. Among these women, the rates of miscarriage and birth defects was not increased above background rates, and there were no infants born with abnormalities consistent with congenital varicella syndrome. Postmarketing data collected since closure of the pregnancy registry has not detected new safety concerns or an increased risk of major birth defects following inadvertent varicella vaccine exposure during pregnancy (Woodward 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Varicella disease during the first or second trimesters may result in congenital varicella syndrome. The onset of maternal varicella infection from 5 days prior to 2 days after delivery may cause varicella infection in the newborn. All women should be assessed for immunity during a prenatal visit; those without evidence of immunity should be vaccinated upon completion or termination of pregnancy (CDC/ACIP [Marin 2007]).</p>
<p style="text-indent:0em;margin-top:2em;">Although the pregnancy registry is closed, any exposures to the vaccine during pregnancy or within 3 months prior to pregnancy should be reported to the manufacturer (Merck &amp; Co, 877-888-4231) or to VAERS (800-822-7967) as suspected adverse reactions.</p></div>
<div class="block mopp drugH1Div" id="F53569430"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Rash, fever; observe for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2023]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.</p></div>
<div class="block pha drugH1Div" id="F233501"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">As a live, attenuated vaccine, varicella virus vaccine offers active immunity to disease caused by the varicella-zoster virus by inducing cell mediated and humoral immune responses</p></div>
<div class="block phk drugH1Div" id="F233516"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Seroconversion occurred in 97% of healthy children ~4 to 6 weeks following a one dose regimen; using a two dose regimen, the seroconversion rate was 99.9% 6 weeks after the second dose. In adolescents≥13 years of age and adults, the seroconversion rate was ~75% 4 weeks after the first dose and 99% 4 weeks after the second dose</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Antibody titers detectable at 10 years postvaccination. Actual antibody titers vary by year and age group, but are ~99% to 100% for children at 10 years and 100% for adolescents and adults at 6 years postvaccination. Exposure to wild-type varicella may boost antibody levels.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F233520"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax ii | Varivax refrigerated | Zostavax</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Provarivax | Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Vacina varicela (atenuada) | Varilrix | Zostavax</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Varicela biken | Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varilrix docpharm | Varivax</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Zostavax</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Zostavax</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Okavax | Varicella vaccine | Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Variped | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Vanrimune | Varicella biken | Varicella vaccine | Varicella zoster h | Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Provarivax | Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Varivax iii | Zostavax</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Okavax | Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Provarivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Okavax | Varilrix | Zostavax</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax Refrigerated</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Zostavax</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(SV)</span> <span class="country">El Salvador</span><span class="countrySeparator">: </span><span class="drugName">Varivax</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax | Zostavax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Varilrix | Varivax</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Varilrix</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Onvara | Varilrix | Zostavax</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-8233746">
<a name="8233746"></a>Bernstein HH, Rothstein EP, Watson BM, et al. Clinical Survey of Natural Varicella Compared With Breakthrough Varicella After Immunization With Live Attenuated Oka/Merck Varicella Vaccine. <i>Pediatrics</i>. 1993;92(6):833-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/8233746/pubmed" id="8233746" target="_blank">8233746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14672472">
<a name="14672472"></a>Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? <i>Obstet Gynecol</i>. 2003;102(5, pt 1):970-977.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/14672472/pubmed" id="14672472" target="_blank">14672472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Vaccination guidance during a pandemic. Updated October 20, 2020. <a href="https://www.cdc.gov/vaccines/pandemic-guidance/index.html" target="_blank">https://www.cdc.gov/vaccines/pandemic-guidance/index.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17360990">
<a name="17360990"></a>Chaves SS, Gargiullo P, Zhang JX, et al. Loss of Vaccine-Induced Immunity to Varicella Over Time. <i>N Engl J Med</i>. 2007;356(11):1121-1129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/17360990/pubmed" id="17360990" target="_blank">17360990</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28398421">
<a name="28398421"></a>Guffey DJ, Koch SB, Bomar L, Huang WW. Herpes zoster following varicella vaccination in children. <i>Cutis</i>. 2017;99(3):207-211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/28398421/pubmed" id="28398421" target="_blank">28398421</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25062334">
<a name="25062334"></a>Krall P, Kubal A. Herpes zoster stromal keratitis after varicella vaccine booster in a pediatric patient. <i>Cornea</i>. 2014;33(9):988-989.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/25062334/pubmed" id="25062334" target="_blank">25062334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.1">
<a name="Kroger.1"></a>Kroger A, Bahta L, Hunter P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 30, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kroger.2">
<a name="Kroger.2"></a>Kroger A, Bahta L, Long S, Sanchez P. General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP). <a href="https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf" target="_blank">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Updated February 10, 2023. Accessed May 1, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1659052">
<a name="1659052"></a>Kuter BJ, Weibel RE, Guess HA, et al. Oka/Merck Varicella Vaccine in Healthy Children: Final Report of a 2-Year Efficacy Study and 7-Year Follow-up Studies. <i>Vaccine</i>. 1991;9(9):643-647.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/1659052/pubmed" id="1659052" target="_blank">1659052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17585291">
<a name="17585291"></a>Marin M, Guris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices; Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2007;56(RR-4):1-40. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/17585291/pubmed" id="17585291" target="_blank">17585291</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NACI.1">
<a name="NACI.1"></a>National Advisory Committee on Immunization (NACI), "Active Vaccines: Varicella Vaccine,” from Public Health Agency of Canada, Ottawa, ONT: Minister of Public Works and Government Services Canada. <a href="https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-24-varicella-chickenpox-vaccine.html" target="_blank">https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/page-24-varicella-chickenpox-vaccine.html</a>. Accessed September 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19837254">
<a name="19837254"></a>Prymula R, Siegrist CA, Chlibek R, et al. Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials. <i>Lancet</i>. 2009;374(9698):1339-1350.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/19837254/pubmed" id="19837254" target="_blank">19837254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24311479">
<a name="24311479"></a>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/24311479/pubmed" id="24311479" target="_blank">24311479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29405375">
<a name="29405375"></a>Song H, Morley KW, Trowbridge RM, et al. Herpes zoster at the vaccination site in immunized healthy children. <i>Pediatr Dermatol</i>. 2018;35(2):230-233.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/29405375/pubmed" id="29405375" target="_blank">29405375</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19747629">
<a name="19747629"></a>Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238. doi:10.1016/j.bbmt.2009.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/19747629/pubmed" id="19747629" target="_blank">19747629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varilrix.1">
<a name="Varilrix.1"></a>Varilrix (varicella virus vaccine) [product monograph]. Mississauga, Ontario, Canada: GlaxoSmithKline Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varivax.2">
<a name="Varivax.2"></a>Varivax (varicella virus vaccine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Varivax.3">
<a name="Varivax.3"></a>Varivax (varicella virus vaccine) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VarivaxIII.1">
<a name="VarivaxIII.1"></a>Varivax III (varicella virus vaccine) [product monograph]. Kirkland, Quebec, Canada: Merck Canada Inc; January 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23922376">
<a name="23922376"></a>Weinmann S, Chun C, Schmid DS, et al. Incidence and clinical characteristics of herpes zoster among children in the varicella vaccine era, 2005-2009. <i>J Infect Dis</i>. 2013;208(11):1859-1868.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/23922376/pubmed" id="23922376" target="_blank">23922376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31392326">
<a name="31392326"></a>Woodward M, Marko A, Galea S, Eagel B, Straus W. Varicella virus vaccine live: a 22-year review of postmarketing safety data. <i>Open Forum Infect Di</i>s. 2019;6(8):ofz295. doi:10.1093/ofid/ofz295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/varicella-virus-vaccine-var-pediatric-drug-information/abstract-text/31392326/pubmed" id="31392326" target="_blank">31392326</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Guiding principles for immunization activities during the COVID-19 pandemic: interim guidance, 26 March 2020. Published March 26, 2020. https://apps.who.int/iris/handle/10665/331590
                  </div>
</li></ol></div><div id="topicVersionRevision">Topic 13006 Version 249.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
